515 related articles for article (PubMed ID: 24816443)
1. Polyglutamine (PolyQ) diseases: genetics to treatments.
Fan HC; Ho LI; Chi CS; Chen SJ; Peng GS; Chan TM; Lin SZ; Harn HJ
Cell Transplant; 2014; 23(4-5):441-58. PubMed ID: 24816443
[TBL] [Abstract][Full Text] [Related]
2. The Expanding Clinical Universe of Polyglutamine Disease.
Huang S; Zhu S; Li XJ; Li S
Neuroscientist; 2019 Oct; 25(5):512-520. PubMed ID: 30614396
[TBL] [Abstract][Full Text] [Related]
3. Autophagy and Polyglutamine Disease.
Ren H; Hao Z; Wang G
Adv Exp Med Biol; 2020; 1207():149-161. PubMed ID: 32671744
[TBL] [Abstract][Full Text] [Related]
4. Increased aggregation of polyleucine compared with that of polyglutamine in dentatorubral-pallidoluysian atrophy protein.
Suzuki Y; Jin C; Yazawa I
Neurosci Lett; 2013 Sep; 552():156-61. PubMed ID: 23933208
[TBL] [Abstract][Full Text] [Related]
5. Machado-Joseph disease and other rare spinocerebellar ataxias.
Matilla-Dueñas A
Adv Exp Med Biol; 2012; 724():172-88. PubMed ID: 22411243
[TBL] [Abstract][Full Text] [Related]
6. Studying polyglutamine diseases in Drosophila.
Xu Z; Tito AJ; Rui YN; Zhang S
Exp Neurol; 2015 Dec; 274(Pt A):25-41. PubMed ID: 26257024
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of SCA3 and implications for other polyglutamine diseases.
McLoughlin HS; Moore LR; Paulson HL
Neurobiol Dis; 2020 Feb; 134():104635. PubMed ID: 31669734
[TBL] [Abstract][Full Text] [Related]
8. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
Bogomazova AN; Eremeev AV; Pozmogova GE; Lagarkova MA
Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
[TBL] [Abstract][Full Text] [Related]
9. A peptidylic inhibitor for neutralizing expanded
Zhang Q; Chen ZS; An Y; Liu H; Hou Y; Li W; Lau KF; Koon AC; Ngo JCK; Chan HYE
RNA; 2018 Apr; 24(4):486-498. PubMed ID: 29295891
[TBL] [Abstract][Full Text] [Related]
10. Cell death in polyglutamine diseases.
Evert BO; Wüllner U; Klockgether T
Cell Tissue Res; 2000 Jul; 301(1):189-204. PubMed ID: 10928291
[TBL] [Abstract][Full Text] [Related]
11. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation.
Mangiarini L; Sathasivam K; Mahal A; Mott R; Seller M; Bates GP
Nat Genet; 1997 Feb; 15(2):197-200. PubMed ID: 9020849
[TBL] [Abstract][Full Text] [Related]
12. [The advances in research on phosphorylation of polyglutamine disease].
Zhou YF; Jiang H; Tang JG; Tang BS
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):414-7. PubMed ID: 18683139
[TBL] [Abstract][Full Text] [Related]
13. Sharing of polyglutamine localization by the neuronal nucleus and cytoplasm in CAG-repeat diseases.
Yamada M; Tan CF; Inenaga C; Tsuji S; Takahashi H
Neuropathol Appl Neurobiol; 2004 Dec; 30(6):665-75. PubMed ID: 15541006
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Nanomedicines for Polyglutamine-Based Neurodegenerative Diseases.
Lee LKC; Leong LI; Liu Y; Luo M; Chan HYE; Choi CHJ
Mol Pharm; 2021 Feb; 18(2):610-626. PubMed ID: 32584043
[TBL] [Abstract][Full Text] [Related]
15. Differential pattern in tissue-specific somatic mosaicism of expanded CAG trinucleotide repeats in dentatorubral-pallidoluysian atrophy, Machado-Joseph disease, and X-linked recessive spinal and bulbar muscular atrophy.
Tanaka F; Sobue G; Doyu M; Ito Y; Yamamoto M; Shimada N; Yamamoto K; Riku S; Hshizume Y; Mitsuma T
J Neurol Sci; 1996 Jan; 135(1):43-50. PubMed ID: 8926495
[TBL] [Abstract][Full Text] [Related]
16. [Triplet repeat disease, with particular emphasis of spinal and bulbar muscular atrophy (SBMA)].
Sobue G
Rinsho Shinkeigaku; 2000 Dec; 40(12):1193-5. PubMed ID: 11464455
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.
Xiang C; Zhang S; Dong X; Ma S; Cong S
Front Mol Neurosci; 2018; 11():153. PubMed ID: 29867345
[TBL] [Abstract][Full Text] [Related]
18. Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations.
Wanker EE
Biol Chem; 2000; 381(9-10):937-42. PubMed ID: 11076024
[TBL] [Abstract][Full Text] [Related]
19. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
Minakawa EN; Popiel HA; Tada M; Takahashi T; Yamane H; Saitoh Y; Takahashi Y; Ozawa D; Takeda A; Takeuchi T; Okamoto Y; Yamamoto K; Suzuki M; Fujita H; Ito C; Yagihara H; Saito Y; Watase K; Adachi H; Katsuno M; Mochizuki H; Shiraki K; Sobue G; Toda T; Wada K; Onodera O; Nagai Y
Brain; 2020 Jun; 143(6):1811-1825. PubMed ID: 32436573
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
